Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method of P<1>,P<4>-di(uridine 5'-)tetraphosphate

A technology of uridine monophosphate triethylamine salt and tetraphosphate, which is applied in the field of P1, can solve the problems of non-residual metal ion research and difficulty in reaching pharmaceutical standards

Active Publication Date: 2020-05-08
SHANGHAI FANGYU HEALTH PHARMA TECH CO LTD
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Chinese patent CN1151166C provides a kind of P1, P4 two (uridine 5,-) tetraphosphate purification method, adopts anion exchange chromatography and active carbon chromatography to purify successively to obtain P 1 , P 4 Bis(uridine 5'-)tetraphosphate tetrasodium salt, with a purity of at least 95%, of which only the impurities UDP and UTP account for about 1%, which is difficult to meet the pharmaceutical standard of less than 1% of the total impurities in the finished product
[0012] At the same time, P 1 , P 4 Di(uridine 5'-) tetraphosphate sodium salt is used as an eye drop preparation, and the residual metal ions of its catalyst should be controlled at an extremely low level. The requirements for eye drops on the residue of heavy metal ions need to control the residue of manganese and zinc below 20ppm, and the prior art has not studied the residue of metal ions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of P&lt;1&gt;,P&lt;4&gt;-di(uridine 5'-)tetraphosphate
  • Preparation method of P&lt;1&gt;,P&lt;4&gt;-di(uridine 5'-)tetraphosphate
  • Preparation method of P&lt;1&gt;,P&lt;4&gt;-di(uridine 5'-)tetraphosphate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] a) Preparation of bistriethylamine pyrophosphate

[0058] Put the pretreated hydrogen-type cation exchange resin PK216 (2.4L) into the chromatography column, add disodium pyrophosphate (75.2g, 282.81mmol) into 1.8L water and stir to dissolve, add the aqueous solution to the hydrogen-type cation-exchange resin In PK216, after soaking for 1 hour, elute with purified water to pH 5.5-6.5, combine the eluents, and titrate the content of pyrophosphoric acid (43.2g, 242.24mmol) and add triethylamine (50.7g, 513.26mmol), Stir for 30min, concentrate under reduced pressure at 45-50°C until white semi-solid, add appropriate amount of N,N'-dimethylformamide (500mL) to the residue for azeotropic dehydration, after concentration is complete, add N,N'- Dimethylformamide, stir evenly to obtain N,N'-dimethylformamide suspension of bistriethylamine pyrophosphate.

[0059] b) Preparation of uridine triethylamine salt

[0060] Put the pretreated hydrogen-form cation exchange resin PK216 ...

Embodiment 2

[0068] a), b), c) steps are the same as in Example 1.

[0069] d)P 1 , P 4 Preparation of Di(uridine 5'-)tetraphosphate

[0070] Mix the N,N'-dimethylformamide solution of uridine acid triethylamine salt obtained in step b) and the N,N'-dimethylformamide solution of imidazole pyrophosphate triethylamine salt obtained in step c) , stirred evenly, added anhydrous manganese chloride (306.2g, 2.43mol) in batches, and controlled the reaction temperature between 25-35°C. After the addition is complete, the mixture is kept under the condition of 25-35° C. and stirred for 2 hours. HPLC detection.

[0071] e) The steps are the same as in Example 1.

Embodiment 3

[0073] a), b), c) steps are the same as in Example 1.

[0074] d)P 1 , P 4 Preparation of Di(uridine 5'-)tetraphosphate

[0075] Mix the N,N'-dimethylformamide solution of uridine acid triethylamine salt obtained in step b) and the N,N'-dimethylformamide solution of imidazole pyrophosphate triethylamine salt obtained in step c) , stirred evenly, added anhydrous manganese chloride (153.5g, 1.22mol) in batches, and controlled the reaction temperature between 25-35°C. After the addition was complete, the mixture was incubated and stirred for 4 hours under the condition of 25-35°C. HPLC detection.

[0076] e)P 1 , P 4 Purification of Di(uridine 5'-)tetraphosphate

[0077] After the reaction was completed, the reaction solution was stirred with 1.8L ethyl acetate, filtered, the solid was dissolved in 1000mL, solid sodium bicarbonate (102.5g, 1.22mol) and sodium carbonate (64.65g, 610mmol) were added, stirred for 2 hours, filtered, the filtrate Add concentrated hydrochloric ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a preparation method of P<1>,P<4>-di(uridine 5'-)tetraphosphate. The method comprises the following steps: under the action of a metal salt catalyst, imidazole triethylamine pyrophosphate shown in formula I and uridine monophosphate triethylamine salt shown in formula II react in N,N-dimethylformamide, and P<1>,P<4>-di(uridine 5'-)tetraphosphate shown in formula III is obtained.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to a P 1 , P 4 The preparation method of di(uridine 5'-)tetraphosphate. Background technique [0002] Diquafosol Tetrasodium (Diquafosol Tetrasodium), the chemical name is P 1 ,P 4 -Di(uridine-5'-)sodium tetraphosphate has been jointly developed into 3% eye drops by Santen Pharmaceutical Company and inspire Pharmaceutical Company for the treatment of dry eye disease. It was launched in Japan in 2010 under the trade name Diquas, The structural formula is as follows: [0003] [0004] The prior art discloses P 1 , P 4 The preparation method of two (uridine 5'-) tetraphosphates, but these preparation methods mostly all will use highly toxic tributylamine, thereby the pollution to environment is bigger. The disclosed preparation methods are: [0005] 1) Uridine diphosphate tributylamine salt self-condenses in the presence of an activator to obtain P 1 , P 4 Di(uridine 5'-)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07H19/10C07H1/00C07H1/06
CPCC07H1/00C07H1/06C07H19/10
Inventor 俞雄戴德明袁西伦张袁伟
Owner SHANGHAI FANGYU HEALTH PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com